FreshBurst Listerine Study Must Exhibit 20% Gingivitis Reduction – FDA
This article was originally published in The Tan Sheet
Executive Summary
A six-month study of FreshBurst Listerine with Fluoride will need to show "a 20% reduction in gingivitis" over the control to receive agency approval, FDA told Pfizer execs at an Aug. 27 meeting
You may also be interested in...
Combination Oral Health Care Products Lack Sufficient Safety Data – J&J
Johnson & Johnson argues against including combination oral health care products in the OTC antingingivitis/antiplaque monograph in Nov. 25 comments to FDA
Combination Oral Health Care Products Lack Sufficient Safety Data – J&J
Johnson & Johnson argues against including combination oral health care products in the OTC antingingivitis/antiplaque monograph in Nov. 25 comments to FDA
Combination Oral Health Care Products Safety Defended By Industry
Marketing of combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association. The group submitted comments to FDA on the subject Nov. 25